Engineering biosafe cisplatin loaded nanostructured lipid carrier: optimisation, synthesis, pharmacokinetics and biodistribution

References

• Ahmad, J., et al., 2014. Solid-nanoemulsion preconcentrate for oral delivery of paclitaxel: formulation design, biodistribution, and γ scintigraphy imaging. BioMed research international, 2014, 984756.
   PubMed Web of Science ®Google Scholar
• Ahmad, S., et al., 2019. Quantification of berberine in berberis vulgaris l. root extract and its curative and prophylactic role in cisplatin-induced in vivo toxicity and in vitro cytotoxicity. Antioxidants, 8 (6), 185.
   Web of Science ®Google Scholar
• Alam, N., et al., 2015. Reduced toxicological manifestations of cisplatin following encapsulation in folate grafted albumin nanoparticles. Life sciences, 142, 76–85.
   PubMed Web of Science ®Google Scholar
• Aldossary, S.A., 2019. Review on pharmacology of cisplatin: clinical use, toxicity and mechanism of resistance of cisplatin. Biomedical and pharmacology journal, 12 (1), 7–15.
   Google Scholar
• Ali, I., et al., 2013. Platinum compounds: a hope for future cancer chemotherapy. Anti-cancer agents in medicinal chemistry, 13 (2), 296–306.
   PubMed Web of Science ®Google Scholar
• Aprille, J.R., and Austin, J., 1981. Regulation of the mitochondrial adenine nucleotide pool size. Archives of biochemistry and biophysics, 212 (2), 689–699.
   PubMed Web of Science ®Google Scholar
• As, K.M., et al., 2020. A review of the preparation, characterization and application of nanostructured lipid carriers. International journal of research in pharmacy and science, 11 (1), 1130–1135.
   Google Scholar
• Badea, M.A., et al., 2018. Cisplatin loaded multiwalled carbon nanotubes induce resistance in triple negative breast cancer cells. Pharmaceutics, 10 (4), 228.
   PubMed Web of Science ®Google Scholar
• Beagloo, I.E., et al., 2019. The antioxidant and hepatoprotective effect of alcoholic extract of ginger against the cisplatin induced oxidative stress in rats. Biomedical journal of scientific & technical research, 19 (2), 14240–14245.
   Google Scholar
• Bhattacharyya, S., and Mehta, P., 2012. The hepatoprotective potential of Spirulina and vitamin C supplemention in cisplatin toxicity. Food & function, 3 (2), 164–169.
   PubMed Web of Science ®Google Scholar
• Chen, K.H., et al., 2015. Nanoparticle distribution during systemic inflammation is size-dependent and organ specific. Nanoscale, 7 (38), 15863–15872.
   PubMed Web of Science ®Google Scholar
• Choi, H.S., et al., 2007. Renal clearance of quantum dots. Nature biotechnology, 25 (10), 1165–1170.
   PubMed Web of Science ®Google Scholar
• Choti, M.A., 2009. Chemotherapy-associated hepatotoxicity: do we need to be concerned? Annals of surgical oncology, 16 (9), 2391–2394.
   PubMed Web of Science ®Google Scholar
• Cohen, S.M., and Lippard, S.J., 2001. Cisplatin: from DNA damage to cancer chemotherapy. Progress in nucleic acid research and molecular biology, 67, 93–130.
   PubMed Web of Science ®Google Scholar
• Das, S., and Chaudhury, A., 2011. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS pharmscitech, 12 (1), 62–76.
   PubMed Web of Science ®Google Scholar
• Das, S., et al., 2011. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables. Colloids and surfaces, 88 (1), 483–489.
   Google Scholar
• Doktorovova, S., Shegokar, R., and Souto, E.B., 2017. Role of excipients in formulation development and biocompatibility of lipid nanoparticles (SLNs/NLCs). In: D. Ficai and A.M. Grumezescu, eds. Nanostructures for novel therapy. Oxford: Elsevier, 811–843.
   Google Scholar
• Duan, X., et al., 2016. Nanoparticle formulations of cisplatin for cancer therapy. Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology, 8 (5), 776–791.
   PubMed Web of Science ®Google Scholar
• El-Shitany, N.A., et al., 2019. Nanoparticles ellagic acid protects against cisplatin-induced hepatotoxicity in rats without inhibiting its cytotoxic activity. International journal of pharmacology, 15 (4), 465–477.
   Web of Science ®Google Scholar
• Eslamifar, Z., and Sabbagh, S., 2020. A histopathological study of cisplatin-induced acute vascular injuries in vital organs and protective effect of Achillea millefolium. Journal of pharmaceutical research international, 30 (10), 56–69.
   Google Scholar
• Esposito, E., et al., 2015. Biodistribution of nanostructured lipid carriers: a tomographic study. European journal of pharmaceutics and biopharmaceutics, 89, 145–156.
   PubMed Web of Science ®Google Scholar
• Garbuzenko, O., et al., 2005. Electrostatics of PEGylated micelles and liposomes containing charged and neutral lipopolymers. Langmuir, 21 (6), 2560–2568.
   PubMed Web of Science ®Google Scholar
• Ghaferi, M., et al., 2020. Enhanced efficacy of PEGylated liposomal cisplatin: in vitro and in vivo evaluation. International journal of molecular sciences, 21 (2), 559.
   PubMed Web of Science ®Google Scholar
• Hamelers, I.H., and De Kroon, A.I., 2007. Nanocapsules: a novel lipid formulation platform for platinum-based anti-cancer drugs. Journal of liposome research, 17 (3–4), 183–189.
   PubMed Web of Science ®Google Scholar
• Hoshyar, N., et al., 2016. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine, 11 (6), 673–692.
   PubMed Web of Science ®Google Scholar
• Jenning, V., Thünemann, A.F., and Gohla, S.H., 2000. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. International journal of pharmaceutics, 199 (2), 167–177.
   PubMed Web of Science ®Google Scholar
• Joseph, E., and Singhvi, G., 2019. Multifunctional nanocrystals for cancer therapy: a potential nanocarrier. In: A.M. Grumezescu, ed. Nanomaterials for drug delivery and therapy. Amsterdam: William Andrew Publishing, 91–116.
   Google Scholar
• Joshi, M., and Patravale, V., 2006. Formulation and evaluation of nanostructured lipid carrier (NLC)–based gel of Valdecoxib. Drug development and industrial pharmacy, 32 (8), 911–918.
   PubMed Web of Science ®Google Scholar
• Kai, M.P., et al., 2015. Evaluation of drug loading, pharmacokinetic behavior, and toxicity of a cisplatin-containing hydrogel nanoparticle. Journal of controlled release, 204, 70–77.
   PubMed Web of Science ®Google Scholar
• Kakkar, P., Das, B., and Viswanathan, P.N., 1984. A modified spectrophotometric assay of superoxide dismutase. Indian journal of biochemistry and biophysics, 21 (2), 130–132.
   PubMed Web of Science ®Google Scholar
• Kelland, L., 2007. The resurgence of platinum-based cancer chemotherapy. Nature reviews. Cancer, 7 (8), 573–584.
   PubMed Web of Science ®Google Scholar
• Khosa, A., Reddi, S., and Saha, R.N., 2018. Nanostructured lipid carriers for site-specific drug Delivery. Biomedicine & pharmacotherapy, 103, 598–613.
   PubMed Web of Science ®Google Scholar
• Köberle, B., et al., 2010. Cisplatin resistance: preclinical findings and clinical implications. Biochimica et biophysica acta, 1806 (2), 172–182.
   PubMed Web of Science ®Google Scholar
• Kumar, V., et al., 2017. Preparation and evaluation of biopolymeric nanoparticles as drug delivery system in effective treatment of rheumatoid arthritis. Pharmaceutical research, 34 (3), 654–667.
   PubMed Web of Science ®Google Scholar
• Kumbhar, D.D., and Pokharkar, V.B., 2013. Engineering of a nanostructured lipid carrier for the poorly water-soluble drug, bicalutamide: physicochemical investigations. Colloids surface A, 416, 32–42.
   Web of Science ®Google Scholar
• Lewis, G.A., Mathieu, D., and Phan-Tan-Luu, R., 1998. Pharmaceutical experimental design. Boca Rotan, FL: CRC Press.
   Google Scholar
• Liu, C.H., and Wu, C.T., 2010. Optimization of nanostructured lipid carriers for lutein delivery. Colloids surface A, 353 (2–3), 149–156.
   Google Scholar
• Liu, J., et al., 2007. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: preparation and characterization. International journal of pharmaceutics, 340 (1–2), 153–162.
   PubMed Web of Science ®Google Scholar
• Madane, R.G., and Mahajan, H.S., 2016. Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, and in vivo study. Drug delivery, 23 (4), 1326–1334.
   PubMed Web of Science ®Google Scholar
• Mansour, H.H., Hafez, H.F., and Fahmy, N.M., 2006. Silymarin modulates cisplatin-induced oxidative stress and hepatotoxicity in rats. Journal of biochemistry and molecular biology, 39 (6), 656–661.
   PubMedGoogle Scholar
• Mehnert, W., and Mäder, K., 2012. Solid lipid nanoparticles: production, characterization and applications. Advanced drug delivery reviews, 64, 83–101.
   Web of Science ®Google Scholar
• Miwa, S., 1972. Hematology. In: N. Kosakai, H. Abe, Y. Hayashi, and T. Furukawa, eds. Modern medical technology. Tokyo, Japan: Igaku Shohin Ltd., 306–310 (in Japanese).
   Google Scholar
• Molpeceres, J., et al., 1996. Application of central composite designs to the preparation of polycaprolactone nanoparticles by solvent displacement. Journal of pharmaceutical sciences, 85 (2), 206–213.
   PubMed Web of Science ®Google Scholar
• Moron, M.S., Depierre, J.W., and Mannervik, B., 1979. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochimica et biophysica acta (BBA)-general subjects, 582 (1), 67–78.
   PubMed Web of Science ®Google Scholar
• Paglia, D.E., and Valentine, W.N., 1967. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. The journal of laboratory and clinical medicine, 70 (1), 158–169.
   PubMed Web of Science ®Google Scholar
• Palipoch, S., and Punsawad, C., 2013. Biochemical and histological study of rat liver and kidney injury induced by cisplatin. Journal of toxicologic pathology, 26 (3), 293–299.
   PubMed Web of Science ®Google Scholar
• Parhizkar, M., et al., 2016. Electrohydrodynamic encapsulation of cisplatin in poly (lactic-co-glycolic acid) nanoparticles for controlled drug delivery. Nanomedicine: nanotechnology, biology, and medicine, 12 (7), 1919–1929.
   PubMed Web of Science ®Google Scholar
• Prabhakar, U., et al., 2013. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer research, 73 (8), 2412–2417.
   PubMed Web of Science ®Google Scholar
• Rahman, Z., Zidan, A.S., and Khan, M.A., 2010. Non-destructive methods of characterization of risperidone solid lipid nanoparticles. European journal of pharmaceutics and biopharmaceutics, 76 (1), 127–137.
   PubMed Web of Science ®Google Scholar
• Ren, G., et al., 2016. Docetaxel prodrug liposomes for tumor therapy: characterization, in vitro and in vivo evaluation. Drug delivery, 23 (4), 1272–1281.
   PubMed Web of Science ®Google Scholar
• Sancho-Martínez, S.M., et al., 2012. Subcellular targets of cisplatin cytotoxicity: an integrated view. Pharmacology & therapeutics, 136 (1), 35–55.
   PubMed Web of Science ®Google Scholar
• Semete, B., et al., 2010. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomedicine: nanotechnology, biology, and medicine, 6 (5), 662–671.
   PubMed Web of Science ®Google Scholar
• Shidhaye, S.S., et al., 2008. Solid lipid nanoparticles and nanostructured lipid carriers-innovative generations of solid lipid carriers. Current drug delivery, 5 (4), 324–331.
   PubMedGoogle Scholar
• Singh, A., et al., 2019. Nanostructured lipid carriers for oral bioavailability enhancement of exemestane: formulation design, in vitro, ex vivo, and in vivo studies. Journal of pharmaceutical sciences, 108 (10), 3382–3395.
   PubMed Web of Science ®Google Scholar
• Singh, D.J., et al., 2012. Development of chitosan-based dry powder inhalation system of cisplatin for lung cancer. Indian journal of pharmaceutical sciences, 74 (6), 521–526.
   PubMed Web of Science ®Google Scholar
• Singh, S., et al., 2010. Formulation and evaluation of solid lipid nanoparticles of a water soluble drug: zidovudine. Chemical & pharmaceutical bulletin, 58 (5), 650–655.
   PubMed Web of Science ®Google Scholar
• Soni, N.K., et al., 2020. Nanostructured lipid carriers potentiated oral delivery of Raloxifene for breast cancer treatment. Nanotechnology, 31 (47), 475101.
   PubMed Web of Science ®Google Scholar
• Sood, S., et al., 2013. Olanzapine loaded cationic solid lipid nanoparticles for improved oral bioavailability. Current nanoscience, 9 (1), 26–34.
   Web of Science ®Google Scholar
• Sultana, S., Verma, K., and Khan, R., 2012. Nephroprotective efficacy of chrysin against cisplatin‐induced toxicity via attenuation of oxidative stress. The journal of pharmacy and pharmacology, 64 (6), 872–881.
   PubMed Web of Science ®Google Scholar
• Tan, S.W., et al., 2010. Surfactant effects on the physical characteristics of Amphotericin B-containing nanostructured lipid carriers. Colloids surface A, 372 (1-3), 73–79.
   Google Scholar
• Teeranachaideekul, V., et al., 2007. Cetyl palmitate-based NLC for topical delivery of coenzyme q10–development, physicochemical characterization and in vitro release studies. European journal of pharmaceutics and biopharmaceutics, 67 (1), 141–148.
   PubMed Web of Science ®Google Scholar
• Verma, A.K., and Sachin, K., 2008. Novel hydrophilic drug polymer nano-conjugates of cisplatin showing long blood retention profile-its release kinetics, cellular uptake and bio-distribution. Current drug delivery, 5 (2), 120–126.
   PubMedGoogle Scholar
• Verma, A.K., Chanchal, A., and Chutani, K., 2012. Augmentation of anti–tumour activity of cisplatin by pectin nano–conjugates in B–16 mouse model: pharmacokinetics and in–vivo biodistribution of radio–labelled, hydrophilic nano–conjugates. International journal of nanotechnology, 9 (10/11/12), 872–886.
   Web of Science ®Google Scholar
• Wang, X., Wang, H., and Song, Y., 2019. Clinical efficacy and mechanism of Pralatrexate combined with Palbociclib Isethionate in treatment of bladder cancer patients. Oncology letters, 17 (1), 201–208.
   Google Scholar
• Wang, Y., et al., 2013. Toxicity and therapy of cisplatin-loaded EGF modified mPEG-PLGA-PLL nanoparticles for SKOV3 cancer in mice. Biomaterials, 34 (16), 4068–4077.
   PubMed Web of Science ®Google Scholar
• Yoon, G., Park, J.W., and Yoon, I.S., 2013. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): recent advances in drug delivery. Journal of pharmaceutical investment, 43 (5), 353–362.
   Google Scholar
• Zheng, D., et al., 2012. In vivo studies on the oridonin-loaded nanostructured lipid carriers. Drug delivery, 19 (6), 286–291.
   PubMed Web of Science ®Google Scholar